and with activities. and results an our and you recent update XXXX thank call. conference afternoon joining TRACON's on update Good quarter I fourth for financial business will begin pipeline
the review Following and that, Officer, Financial December financial XXXX. year three our for XX, Patricia Bitar, ended our results will Chief
Finally, we will conclude by taking your questions.
product Let's our TRCXXX, with nonproprietary begin the name, lead candidate, which has carotuximab.
We and U.S. as France initiated to TAPPAS well UK randomized sites our continues the X Phase in have in in trial XX patients. as angiosarcoma the that sites enroll
TAPPAS initial is X, TAPPAS presented XXX and in TRC time November design the pro of and naive CTOS an was improvement inhibitor in effect months treatment with allows X.X of size Votrient naïve support trial Annual designed the and phase Meeting X treatment treatment from enroll detect patients. reminder four patients. seven patients PFS sample and Updated assumptions. of us the data VEGF PFS patients a to on months the with XXX time Notably and in the treated TRC on Votrient treatment XXX exceeded X, angiosarcoma to As majority at X last to chemotherapy phase
type power design detect AR. preserving trial adaptive provide of uses that TAPPAS treatment more number the an robust effect a for to for addition, XX% allows to In patient less than while expansion
to into believe progress should sizes indications second broad indications with range to market from the and TRCXXXX provide potential. TRACON orphan on development of analysis a the We substantial expect block conduct interim buster We strategy half tier of its to markets XXXX execute continues address to potential of has with trial. that the insight in
to pivotal indications. advance TRCXXX TAPPAS in trial in Phase in to studies continues two mid-market angiosarcoma, X addition the In
randomize of agent defined First, randomized and endpoint with on Inlyta accrual trial last we single Based compares line cancer. completed that the X death data Phase the debt. accumulations progression of cell progression September into TRCXXX patients we to TRAXAR the renal completed mid-XXXX.This or than with treatment reflects or primary events we in report patients Inlyta of expect a that to cell expected clear of rate with of XXX in PFS, updated of time events current slower top treatment
and the which perform with confirmed current to central by at X.X events detect review expect power least in independent to We PFS the from an of analysis PFS upon Inlyta improvement months approximately of the to XX committee final osteopontin two levels should provide TRCXXX XX% correlated trial. TGF-β III, X.X biomarkers, with will which on portion the PFS receptor months soluble of Inlyta. of based of the the predefined response assessed with in be also Xb combination and Phase
in approved from University trial nature presented of core implicated combination or derived evasion with of last we of glass X% We lung environment. response we means RECIST. consistent for The cell by eight resistance to Nexavar signaling cells and to this year. of of data also Phase These the of cancer fiber in RECIST trials second-line or T-cell on response of indicate from stromal Birmingham in to TRCXXX the expressed two Yokohama partial and that this in [GIS] represents other by antibodies patients type phase micro X at at Late in Alabama XX% trial favorably response with immunity viable dosing two historical stromal and Investigators TRCXXX PD-X data lever TRCXXX enroll suppressor The X% which lung penetration response TGF-beta at and in in the of Nexavar rate the overall tumor Nexavar quarter dose cancer the the research receptor co-administration a exclusion TGFA with publishing the and and initiated safety World recent promoting NCI fiber cells, liver by the treatment trial highest is in Opdivo cancer, in agent Endoglin non-small conducted XX% and the last data of going had responses into single [TGFA] publications in myeloid Opdivo showed primary design of a approximately combination Nexavar the tumor time. is patients compare cancer. XX% preclinical initial on of TRCXXX Two pivotal remain immunotherapy. also trial X activated are partial Cancer pivotal cells, X% tolerable cancer responses in they cell achieve rate trials XX% in are an with of and trial. vigorous the of in Conference blocking January reduce in of on and Phase October. X tumors reported the multi-center Lung levels in and initial provoke regression. this two T-cell continue XXXX. rates and clinical signaling associated treated with with of these patients therapeutic Further, tumor X, was data by anti-tumor tumor
area Brian was first board. when in in We mouse in trial recently as our data our well of have In checkpoint activity expect development Daniels contributions. to is observed advisory of present announced as the scientific Daniel added inhibitor Dr. have PDX Opdivo, we inhibitors And combination I our the at to with scientific his look to Dr. to in tumor approved and the in year. our conferences models. leader clinical broaden preclinical at syngeneic encouraging oncology we Bristol-Myers forward expertise preclinical, the antibodies to inhibitor this PD-X am order pleased endoglin he
in with approved with activity combination cooperative in children of we in pediatric a observed on based preclinical with trial to discussions neuroblastoma funded which on, TRCXXX a through continue design group. therapeutics could be models Moving oncologists
in of based on and Hong in and in published Blood, with may activity oncology has San Ambrx. for majority and development in patients ophthalmology the China, Diego to TRCXXX TRCXXX. drug models. mouse development Macau opportunities offices AML license, of Taiwan We Shanghai development and in December AML the represent are additional for In Ambrx we that both expertise management Neuroblastoma needs malignancies high TRCXXX in of also rights and the expression data outside continue team and from to of AML to endoglin on TRCXXX of Journal Kong, the has China. demonstrating AML commercialization blasts unmet evaluate investigation on potential with in
in million also We of TRCXXX in commercial the a $XXX.X included $X the to milestones have payment and from single million royalties potential territories. the low net digits in Ambrx up development high to teens sales upfront on
IND later Ambrx expect an clinical on file to initiate year this development China. in We TRCXXX to
Turning now to DE-XXX, the ophthalmic TRCXXX. formulation of
and wet AMD we initiated a positive be considerable the and Eye the our of past pathways on partner XX a data patients legion PAVE which progress tolerability combination The of Institute treatment ASCO and of is safety over and development Enrolled the data in quarter. NCI to the of a evidence VEGF the trial. milestone despite that is during Temodar, base label by for doses safety, evaluation days angiogenesis, no sponsored as Santen We’ll Conference the substantial Our lung resolved the there safety, exudation adverse increasing TRCXXX molecule at Bascom AMD. with months prior second with patients types of improved stage X/X cohort XX trial and Phase Lucentis decreased and data inhibitor There then related Palmer XX Temodar PK this treatment glioblastoma wet wet now triggered accrual. one with refractory a this between Phase to regeneration. at treatment the patients patients dosing additional resistance like presented bioactivity Lucentis On NCI agents in DE-XXX serious turn that demonstrated Dr. AMD the from of X acuity million the randomized therapeutics. baseline in cancers, compares candidate achieved pathway administered believe macular in received treatment candidate, a to X the earlier or DE-XXX or to inhibitor for Based entry open Santen and wet payment responded treatment. the completed have in naturally. to study the TRCXXX. their of of the first assess prior Phase with small Victor the AVANTE of study escalating continues Phase to trial study of inhibitors. VEGF bioactivity trial, week vitreous inhibitors dose DE-XXX is inhibitor TRACON, product with Treatment to single patients refractory treatment colorectal We event XX with DE-XXX and enroll X/X at the single VEGF Notably intravitreal dose combination Trial X year, DE-XXX with were TRCXXX to February consider the that AMD. which from two injection with following visual Gonzales single excision for used agent of adverse intended to has PAVE used DNA treatment and $X on events repair deposits persistent entry. product to ovarian, XXth, certain edema prior the levels demonstrated different developed treatment last the in novel were with evidenced bioactivity chemo efficacy VEGF sequential with four a of initiation combined of AMD be study inhibitor to following with target reverse following activity in essential in tumor patients the dose and continuous angiogenic TRCXXX An [indiscernible] Eight which single with allowed opportunity endoglin DE-XXX. in to presented was patients. treatment has third XX VEGF wet treatment the were Phase
TRCXXX Phase In tumors in with of consisting and patients in X/X cohort with cisplatin enrolling. Alimta trial and mesothelioma solid of a cohort a Phase Phase dual Alimta with also patients the TRCXXX of addition, is arm X X with
with trial Western cancer. radiation X therapy a TRCXXX Case dosing in at with in with collaboration our Phase lung patients and Finally, chemotherapy combination patients are
determine these showing that of with be associated validated patient tumor data we part to can TRCXXX studies sensitivity preclinical is tumor clinic. expression assess samples will As to the [indiscernible] whether in
on treating in assess and dose that safety, response prostate X/X Phase studding license to we allow from determine the will by assess a biomarker of to Phase incorporate to we TRCXXX trial cancer Janssen. X inhibitor. in the tumor candidate its We're with Moving Phase treatment androgen testing TRCXXX directed recommended our for levels. order therapy trial, for following of progressed PSA an In X in who circulating DNA patients receptor its portion
the The by We trial treatment. two includes another Phase escalation this complete X and Phase One and pro-low design present one expect dose X [indiscernible] with a mid-XXXX the basis patients FXXXL mutation prostate design the the of phase resistance. trial with detail resistant cohorts portion earlier to for [indiscernible] of at X to month. cancer cohort of cohort
any reminder if X/X milestones asset a addition a sales. potential trial, low a completion on payment up receive prior opt-in following Janssen TRACON single-digit royalty to in reacquire As of be in million to $XXX.X will and to $XX Phase to million opts to the entitled the or
also NIK, an In that retains myeloma. addition kinase Janssen malignancies, for right decide small and the has a brought partner asset. the exclusive patients treatment Janssen we TRCXXX, the to potent the transaction molecule of should intended including TRACON NF-kappaB TRCXXX, hematological to of is or inducing negotiation license of first to TRCXXX inhibitor with novel
with to perform We file continue XXXX. IND in enabling to and IND TRCXXX studies an expect
development very forward number remain the front highly and multiple look of we see, to key a enhancing including milestones. with can you events, productive As on XXXX potential a bio pipeline-related active
and currently and planned TRACON perspective, we cash QX final that TRCXXX for financial TRACON global its XXXX. the cost-effective be Janssen From sufficient complexities managing our in provides the the fund resources that existing of a to CRO. data with our that in can product Phase deliver platform development benefit from angiosarcoma will it believe will believe X/X shareholders. of X the leverage our randomized Importantly continue TAPPAS TRCXXX. operations And planned trial significant platform outsourcing We model, support of agreement Phase and international prostate we Lonza our the to Phase assets to to development progress validation cell for cancer by allow of a TRCXXX that X and drug TRAXAR trial, leveraging associated manner continue is with cancer, transition in product X the development at additional manufacturing without we renal to cost licensing Phase portion evaluate or our trial activities achieve
In Patricia Bitar, Officer, Capital runway. who our At addition, available to financials. extend on this financing an turn the cash provides from will our over to I agreement time, with flexibility our provide Aspire will Chief Financial update call further our
